ITRM
Iterum Therapeutics Plc
Halal Rating :
Last Price
$1.53
Last updated:
Market Cap
-
7D Change
-6.71%
1 Year Change
-19.47%
Company Overview
Industries
Exchange
Next Earnings Date
Iterum Therapeutics plc is a clinical-stage pharmaceutical company focused on developing next-generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings. Their lead product candidate is sulopenem, an antibiotic designed to treat uncomplicated urinary tract infections.
The company is currently in development phase and has not yet commercialized any products. They are primarily engaged in research and development activities.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|
Company Impact
Help us evaluate Iterum Therapeutics Plc's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.